[Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma].
To evaluate the clinical significance of microvessel density (MVD) and investigate the relationship of Endoglin (CD105), VEGF and p53 protein and their significance of clinical pathology. Pathologic paraffin-embedded tissues and clinic data of 40 patients with primary squamous cell carcinoma of larynx were studied. Serial sections were respectively stained with Endoglin (CD105), VEGF and p53 by immunohistochemistry and its expressions were investigated. Microvessel density (MVD) highlighted by Endoglin (CD105) were counted according to a standard protocol. Endoglin (CD105) expression in tumour tissue was significantly higher than in normal mucosa (P < 0.05). The mean MVD value for Endoglin (CD105) was 14. 90 +/- 7.40. The mean CD105-MVD value of T3 and T4 tumours showed a significantly higher staining than that of T1 and T2 tumours; The mean CD105-MVD value of tumours with metastasis was also higher than that of tumours with no metastasis (P < 0.05); The expression of VEGF was observed in cytoplasm of tumour cell and its positive rate was 77.5% in laryngeal carcinoma, which was significantly correlated with TNM stage and pathological differentiation of laryngeal carcinoma (P < 0.05). The expression of p53 protein was mainly observed in nucleolus of tumour cell and its positive rate was 67.5%, which was significantly correlated with metastasis of lymph node. Positive relevance was found between CD105-MVD and VEGF (r = 0.641, P < 0.01); Positive relevance was also found between CD105-MVD and p53 (r = 0.534, P < 0.01). Endoglin (CD105) is a marker of tumour angiogenesis for its significant associated with active angiogenesis in laryngeal carcinoma. The study shows that CD105-MVD in laryngeal carcinoma is an independent indicator of predicting invasion, metastasis and recurrence, and evaluating prognosis of malignant tumours. CD105-MVD, VEGF and p53 could be important indicators to evaluate invasion, metastasis and recurrence of laryngeal carcinoma.